M ore than 33 million people have atrial fibrillation worldwide, 1 and the prevalence is expected to double in the coming decades. 2,3 Atrial fibrillation is associated with a fivefold increase in the risk of stroke, 4,5 for which the 1-year mortality rate is 50%. 6 Stroke prevention with oral anticoagulation therapy decreases the risk by about 60%, 7,8 and numerous guidelines endorse this type of therapy for high-risk patients with atrial fibrillation. 9-11 Nonetheless, many studies have documented suboptimal use of oral anticoagulants. [12][13][14] Patients with atrial fibrillation often present to the emergency department because of symptoms such as palpitations, shortness of breath and chest pain. 15,16 In Ontario, there are about 20 000 emergency department visits per year for atrial fibrillation, and most of these patients (63%) are sent home after emergency care (v. 31% in the United States). 17 Therefore, the emergency department may be an important setting for improvement of suboptimal prescribing rates for oral anticoagulants. [18][19][20] The advent of direct oral anticoagu lants, 21-24 which do not require bridging or monitoring of the international normalized ratio, may improve the willingness of emergency physicians to initiate a long-term medication that may cause bleeding. However, current usual care is referral to the longitudinal care provider (e.g., primary care provider or cardiologist) to initiate such medications, as that provider will have the patient's complete medical history, can follow the patient for potential adverse effects and dose adjustments, and has more time for shared decision-making, possibly over more than 1 visit. 25,26 In addition, there are limited data on whether initiation of oral anticoagulants in the emergency department results in greater long-term use. 27 We assessed the long-term use of oral anticoagulants after provision of a prescription in the emergency department, compared with deferral to the longitudinal health care provider for initiation of therapy.